BLR&D Research Career Scientist Award Application

BLR

• 批准号: 10515313
• 负责人: HUIPING Rose ZHOU
• 金额: --
• 依托单位: VA VETERANS ADMINISTRATION HOSPITAL
• 依托单位国家: 美国
• 财政年份: 2018
• 资助国家: 美国
• 起止时间: 2018-10-01 至 2023-09-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10515313
• 关键词: Acids; Address; Alcoholic Fatty Liver; Alternative Medicine; Animal Model; Animals; Archives; Award; Berberine; Bile Acids; Cholangiocarcinoma; Cholestasis; Clinical; Clinical Trials; Collaborations; Communication; Communities; Development; Disease Progression; Estrogens; Ethics; Event; FDA approved; Faculty; Foundations; Funding; Future; Gastroenterology; Gastrointestinal Injury; Genetic; Glycolates; Goals; Grant; H19 gene; HIV; HIV Protease Inhibitors; Health; Healthcare; Hepatic; Hepatocyte; Hepatology; Homeostasis; Immunology; Internal Medicine; Knockout Mice; Laboratories; Link; Lipids; Liver diseases; Mediating; Medical Research; Medical center; Medicinal Plants; Messenger RNA; Metabolic Diseases; Microbiology; Mission; Molecular; Natural Products; Pathogenesis; Pathologic; Peer Review; Pharmaceutical Preparations; Pharmacologic Substance; Pharmacology; Physiological; Plants; Play; Positioning Attribute; Publishing; RNA-Binding Proteins; Reporting; Research; Research Personnel; Research Project Grants; Role; Scientist; Services; Signal Pathway; Sphingolipids; Taurine Cholate; Techniques; Therapeutic; Therapeutic Agents; Therapeutic Effect; Tissues; Toxicology; United States National Institutes of Health; Universities; Untranslated RNA; Veterans; Virginia; Work; base; career; clinical development; drug induced liver injury; effective therapy; endoplasmic reticulum stress; extracellular; fatty liver disease; inorganic phosphate; lipid metabolism; liver injury; medical schools; military veteran; non-alcoholic fatty liver disease; nonalcoholic steatohepatitis; novel; novel therapeutic intervention; novel therapeutics; patient population; prevent; professor; programs; protective effect; receptor; side effect; therapeutically effective

AIMS: The goal of this application is to apply for Research Career Scientist (RCS) Award and to support Dr. Huiping Zhou’s VA research program. NOMINEE: Dr. Zhou has held a VA Research Chemist position since 2008, and she also holds the title of Tenured Professor in the Department of Microbiology and Immunology at Virginia Commonwealth University School of Medicine in Richmond, Virginia. Dr. Zhou’s research program has been continuously funded by VA MERIT Review Awards, NIH R01 grants, several local foundations and pharmaceutical companies since she established her independent research program in 2004. Dr. Zhou has made significant contributions to scientific research fields related to liver injury and metabolic diseases throughout her career, and published more than 100 peer- reviewed original research articles that have created more than 6000 citations. In addition, Dr. Zhou acts as a co-investigator in several VA-sponsored research projects. Research: Studies in Dr. Zhou’s laboratory are to investigate the mechanisms underlying drug- induced liver injury and the role of bile acid-mediated signaling pathways in hepatic lipid metabolism under physiological and pathological conditions, and to further search for new and more effective therapies to prevent and treat metabolic diseases. Disruption of hepatic bile acid homeostasis occur commonly in various pathological states such as non-alcoholic fatty liver disease (NAFLD), alcoholic fatty liver disease (ALD), cholestatic liver diseases as well as drug- induced liver injury. Since the exact mechanisms underlying bile acid-mediated liver injury and metabolic diseases are still obscure, effective therapeutics are limited. Dr. Zhou’s research is highly focused on identification of novel cellular/molecular mechanisms involved in disease progression of NAFLD, ALD and cholestatic liver diseases. Dr. Zhou’s research employs the stat- of-the-art techniques, including isolation and culture of various hepatic cells, examine specific messenger RNA (mRNA), non-coding RNA (ncRNA), mRNA/ncRNA/RNA –binding proteins (RBP) interactions and extracellular vehicles-mediated communications. Dr. Zhou’s group has established animal models for NAFLD/NASH, ALD, and cholestasis. Her group has also extensively used genetic modified animals including tissue-specific knockout mice. The overreaching goal of Dr. Zhou’s research program is to elucidate the cellular/molecular mechanisms that govern hepatic lipid homeostasis and to create a fundamental base for development of new therapeutics for various liver diseases. IMPACT: Dr. Zhou’s research program directly addresses an important health issue relevant to the VA mission, since NAFLD/NASH, ALD and cholestatic liver diseases occur commonly in our VA patient population. Dr. Zhou is also actively collaborates a number of investigators in the Research service of the McGuire VA Medical Center. Her expertise and academic activity help promoting VAMHCS research.

目的：申请的目的是申请研究职业科学家（RCS）奖和 支持Huiping Zhou的VA研究计划。 提名人：周博士自2008年以来一直担任VA研究化学家职位，她也担任 弗吉尼亚州微生物和免疫学系的终身教授名称 弗吉尼亚州里士满的联邦大学医学院 计划一直由VA优异审查奖，NIH R01赠款，严重性不断资助 自从她建立了坚定的研究以来，地方基金会和制药公司 2004年的计划。周博士为与科学研究领域有关 在整个职业生涯中，肝损伤和代谢疾病，并出版了100多个同伴 审查了原始的研究文章，这些文章还引用了6000多个。 周在几个VA赞助的研究项目中充当了共同投资者。 研究：Zhou博士实验室的研究是为了研究药物的基础机制 诱导的肝损伤和胆汁酸介导的信号通路的胆汁在肝脂质中的作用 在生理和病理状况下的代谢，并进一步寻找新的和 预防和治疗代谢疾病的更有效疗法。 稳态通常发生在各种病态状态，例如非酒精脂肪肝 疾病（NAFLD），酒精脂肪肝病（ALD），胆汁疾病肝病以及药物 诱导肝损伤，因为胆汁酸介导的肝损伤的确切机制 代谢性疾病仍然晦涩难懂，有效的疗法是有限的。 高度专注于鉴定涉及疾病的新型细胞/分子机制 NAFLD，ALD和胆汁淤积性肝病的进展。 艺术技术，包括各种肝细胞的隔离和培养，检查特定 信使RNA（mRNA），非编码RNA（NCRNA），mRNA/ncRNA/RNA结合蛋白（RBP） 相互作用和细胞外车辆介导的通信。 NAFLD/NASH，ALD和CHOLESTASIS已建立的动物模型也已有。 广泛使用的遗传修饰动物包括组织特异性敲除小鼠 周博士研究计划的推广目标是阐明细胞/分子 控制肝脂质稳态的机制，并为 开发各种肝病的新疗法。 影响：Zhou博士的研究计划直接解决了重要的健康状况。 VA任务，因为NAFLD/NASH，ALD和胆汁淤积性肝脏疾病通常发生在我们 弗吉尼亚州的患者人数也积极合作 McGuire VA医疗中心的研究服务。 促进VAMHCS研究。